{"id":"rifampin-randomized-open-label","safety":{"commonSideEffects":[{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Discoloration of body fluids (orange-red)"},{"rate":null,"effect":"Gastrointestinal disturbances"},{"rate":null,"effect":"Rash"},{"rate":null,"effect":"Drug interactions (enzyme induction)"}]},"_chembl":{"chemblId":"CHEMBL374478","moleculeType":"Small molecule","molecularWeight":"822.95"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Rifampin is a rifamycin antibiotic that binds to the bacterial RNA polymerase enzyme, specifically the β-subunit, and inhibits RNA synthesis. This prevents bacteria from transcribing DNA into RNA, which is essential for protein production and survival. It is bactericidal and has broad-spectrum activity against many gram-positive and gram-negative bacteria, as well as mycobacteria.","oneSentence":"Rifampin inhibits bacterial RNA polymerase, preventing transcription and blocking bacterial protein synthesis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:32:09.308Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Tuberculosis"},{"name":"Mycobacterial infections"},{"name":"Bacterial infections (as part of combination therapy)"}]},"trialDetails":[{"nctId":"NCT04930744","phase":"PHASE2","title":"Safety and Tolerability of Metformin in People With Tuberculosis (TB) and Human Immunodeficiency Virus (HIV)","status":"COMPLETED","sponsor":"University of Massachusetts, Worcester","startDate":"2021-08-26","conditions":"Tuberculosis, Pulmonary Tuberculosis, HIV Coinfection","enrollment":112},{"nctId":"NCT06192160","phase":"PHASE2","title":"Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-03-11","conditions":"Pulmonary Tuberculosis","enrollment":315},{"nctId":"NCT07350174","phase":"PHASE2","title":"Phase 2a Trial of Alpibectir Plus Ethionamide for Tuberculosis Meningitis","status":"NOT_YET_RECRUITING","sponsor":"BioVersys AG","startDate":"2026-03-30","conditions":"Tuberculosis Meningitis","enrollment":64},{"nctId":"NCT05556746","phase":"PHASE2","title":"Ultra-Short Course Bedaquiline, Clofazimine, Pyrazinamide and Delamanid Versus Standard Therapy for Drug-Susceptible TB","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2023-11-24","conditions":"Tuberculosis, Pulmonary, HIV","enrollment":94},{"nctId":"NCT07209761","phase":"PHASE3","title":"A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary Tuberculosis","status":"RECRUITING","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2025-10-16","conditions":"Pulmonary Tuberculosis","enrollment":532},{"nctId":"NCT07069582","phase":"PHASE1","title":"Pharmacokinetics of Antituberculosis Drugs in Breastfeeding Women","status":"NOT_YET_RECRUITING","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2026-04-01","conditions":"Tuberculosis Infection, Healthy Volunteer, Breastfeeding","enrollment":60},{"nctId":"NCT07170800","phase":"PHASE2","title":"A Phase 2b Clinical Study of JDB0131 Benzenesulfonate Tablets","status":"RECRUITING","sponsor":"WestVac Biopharma Co., Ltd.","startDate":"2025-09-19","conditions":"Tuberculosis, Multidrug Resistant Pulmonary Tuberculosis, Rifampicin-resistant Tuberculosis","enrollment":60},{"nctId":"NCT05074147","phase":"PHASE3","title":"Comparison Between Two Durations of Antibiotherapy for Non-surgically-treated Diabetic Foot Osteomyelitis (CHRONOS-2)","status":"WITHDRAWN","sponsor":"Tourcoing Hospital","startDate":"2022-05-01","conditions":"Osteomyelitis - Foot","enrollment":""},{"nctId":"NCT04630145","phase":"PHASE2, PHASE3","title":"A Study of Bedaquiline Administered as Part of a Treatment Regimen With Clarithromycin and Ethambutol in Adult Patients With Treatment-refractory Mycobacterium Avium Complex-lung Disease (MAC-LD)","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2021-01-08","conditions":"Treatment-refractory Mycobacterium Avium Complex-lung Disease (MAC-LD)","enrollment":129},{"nctId":"NCT05383742","phase":"PHASE2","title":"Trial of a Six-Month Regimen of High-Dose Rifampicin, High-Dose Isoniazid, Linezolid, and Pyrazinamide Versus a Standard Nine-Month Regimen for the Treatment of Adults and Adolescents With Tuberculous Meningitis","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-12-07","conditions":"Tuberculous Meningitis","enrollment":330},{"nctId":"NCT05807399","phase":"PHASE2","title":"PanACEA - STEP2C -01","status":"RECRUITING","sponsor":"Michael Hoelscher","startDate":"2023-04-14","conditions":"Pulmonary Tuberculosis, Other Specified Pulmonary Tuberculosis","enrollment":390},{"nctId":"NCT06199921","phase":"PHASE2","title":"ATORvastatin in Pulmonary TUBerculosis","status":"RECRUITING","sponsor":"Obafemi Awolowo University Teaching Hospital","startDate":"2024-01-03","conditions":"Pulmonary Tuberculosis, Tuberculosis, Koch's Disease","enrollment":440},{"nctId":"NCT03915366","phase":"PHASE2, PHASE3","title":"Empirical Treatment Against Cytomegalovirus and Tuberculosis in HIV-infected Infants With Severe Pneumonia","status":"COMPLETED","sponsor":"Hospital Universitario 12 de Octubre","startDate":"2020-03-01","conditions":"Pneumonia, HIV/AIDS, Tuberculosis","enrollment":563},{"nctId":"NCT07056842","phase":"PHASE1","title":"This is an Open-label, Non-randomized Study to Assess the Pharmacokinetics (PK) of VCT220 in Healthy Volunteers When Administered With Rifampin or Itraconazole","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vincentage Pharma Co., Ltd","startDate":"2025-07-20","conditions":"Obesity &Amp; Overweight","enrollment":32},{"nctId":"NCT05221502","phase":"PHASE2","title":"Safety and Efficacy Evaluation of 4-month Regimen of OPC-167832, Delamanid and Bedaquiline in Participants With Drug-Susceptible Pulmonary TB","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2022-04-12","conditions":"Pulmonary TB","enrollment":122},{"nctId":"NCT06081361","phase":"PHASE3","title":"Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis：Contezolid, Delamanid and Bedaquiline Cohort","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beijing Chest Hospital","startDate":"2023-12-22","conditions":"Pulmonary Tuberculosis, Rifampicin-resistant Tuberculosis","enrollment":186},{"nctId":"NCT06191692","phase":"PHASE3","title":"1HP Versus 3HR in the Treatment of Tuberculosis Infection in Vietnam","status":"NOT_YET_RECRUITING","sponsor":"Freundeskreis Für Internationale Tuberkulosehilfe e.V","startDate":"2025-08-01","conditions":"Tuberculosis Infection","enrollment":350},{"nctId":"NCT06748937","phase":"PHASE2","title":"A Study of the Early Effects, Safety, and Acceptability of Oral Alpibectir in Combination With Ethionamide","status":"RECRUITING","sponsor":"TASK Applied Science","startDate":"2025-03-03","conditions":"Tuberculosis","enrollment":60},{"nctId":"NCT02770222","phase":"PHASE1","title":"A Clinical Study to Investigate the Effect of Gemfibrozil or Rifampicin on Blood Concentrations of Selexipag in Healthy Subjects","status":"COMPLETED","sponsor":"Actelion","startDate":"2016-06","conditions":"Healthy Subjects","enrollment":40},{"nctId":"NCT02410772","phase":"PHASE3","title":"TBTC Study 31: Rifapentine-containing Tuberculosis Treatment Shortening Regimens","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2016-01-25","conditions":"Tuberculosis","enrollment":2516},{"nctId":"NCT06658964","phase":"PHASE1","title":"Study to Evaluate the Drug-drug Interaction of JMKX003142 in Healthy Subjects","status":"NOT_YET_RECRUITING","sponsor":"Jemincare","startDate":"2024-11-05","conditions":"ADPKD (autosomal Dominant Polycystic Kidney Disease)","enrollment":48},{"nctId":"NCT04062201","phase":"PHASE3","title":"Building Evidence for Advancing New Treatment for Rifampicin Resistant Tuberculosis (RR-TB) Comparing a Short Course of Treatment (Containing Bedaquiline, Delamanid and Linezolid) With the Current South African Standard of Care","status":"COMPLETED","sponsor":"Wits Health Consortium (Pty) Ltd","startDate":"2019-08-22","conditions":"Tuberculosis, Pre-XDR-TB, Extensively Drug-Resistant Tuberculosis","enrollment":402},{"nctId":"NCT06348290","phase":"PHASE1","title":"Study to Evaluate the Drug-drug Interaction of JMKX001899 in Healthy Subjects","status":"NOT_YET_RECRUITING","sponsor":"Jemincare","startDate":"2024-04-01","conditions":"Solid Tumor, Adult","enrollment":72},{"nctId":"NCT06332053","phase":"PHASE1","title":"A Study to Evaluate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics of SY-5007 in Healthy Subjects","status":"NOT_YET_RECRUITING","sponsor":"Shouyao Holdings (Beijing) Co. LTD","startDate":"2024-04-01","conditions":"Healthy Subjects","enrollment":28},{"nctId":"NCT03338621","phase":"PHASE2, PHASE3","title":"Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients","status":"COMPLETED","sponsor":"Global Alliance for TB Drug Development","startDate":"2018-07-30","conditions":"Tuberculosis, Pulmonary, Tuberculosis, Multidrug-Resistant, Tuberculosis, MDR","enrollment":455},{"nctId":"NCT05917340","phase":"PHASE3","title":"Intensified Short Course Regimen for TBM in Adults","status":"NOT_YET_RECRUITING","sponsor":"Indian Council of Medical Research","startDate":"2024-03","conditions":"Tuberculous Meningitis","enrollment":372},{"nctId":"NCT03678688","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Trial of Multiple Oral Doses of OPC-167832 for Uncomplicated Pulmonary Tuberculosis","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2018-10-18","conditions":"Pulmonary TB","enrollment":122},{"nctId":"NCT02256696","phase":"PHASE2","title":"Assessing PA-824 for Tuberculosis (the APT Trial)","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2015-04-29","conditions":"Pulmonary Tuberculosis","enrollment":157},{"nctId":"NCT03982277","phase":"PHASE2","title":"Safety and Efficacy of High Dose Rifampicin in Tuberculosis (TB)-HIV Co-infected Patients on Efavirenz- or Dolutegravir-based Antiretroviral Therapy","status":"COMPLETED","sponsor":"Makerere University","startDate":"2019-04-30","conditions":"Tuberculosis","enrollment":130},{"nctId":"NCT04044001","phase":"PHASE1, PHASE2","title":"BTZ-043 - Multiple Ascending Dose (MAD) to Evaluate Safety, Tolerability and Early Bactericidal Activity (EBA)","status":"COMPLETED","sponsor":"Michael Hoelscher","startDate":"2019-11-15","conditions":"Pulmonary Tuberculoses, Other Specified Pulmonary Tuberculosis","enrollment":77},{"nctId":"NCT03530995","phase":"PHASE1","title":"Drug-drug Interaction Between Belumosudil, Itraconazole, Rifampicin, Rabeprazole, and Omeprazole in Healthy Volunteers","status":"COMPLETED","sponsor":"Kadmon Corporation, LLC","startDate":"2018-04-09","conditions":"Drug-drug Interaction, Autoimmune Diseases, Fibrotic Disease","enrollment":73},{"nctId":"NCT04672525","phase":"PHASE3","title":"Rifabutin Versus Rifampicin for Treatment of Staphylococcal PJI Treated With DAIR","status":"RECRUITING","sponsor":"Tourcoing Hospital","startDate":"2021-11-08","conditions":"Prosthetic Infection","enrollment":436},{"nctId":"NCT04553406","phase":"PHASE2","title":"Safety, Tolerability, Pharmacokinetics and Efficacy of SPR720 for the Treatment of Patients With Mycobacterium Avium Complex (MAC) Pulmonary Disease","status":"TERMINATED","sponsor":"Spero Therapeutics","startDate":"2020-12-03","conditions":"Mycobacterium Avium Complex, Non-tuberculous Mycobacterium Pulmonary Disease","enrollment":2},{"nctId":"NCT03819114","phase":"PHASE2","title":"Pharmacokinetic Study to Evaluate Double-Dose Levonorgestrel Emergency Contraception in Combination With Efavirenz-Based Antiretroviral Therapy or Rifampicin-Containing Anti-Tuberculosis Therapy","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2019-05-06","conditions":"HIV Infections, Tuberculosis","enrollment":122},{"nctId":"NCT02958709","phase":"PHASE1, PHASE2","title":"Optimizing Treatment to Improve TBM Outcomes in Children","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2017-02-22","conditions":"Tuberculosis, Meningeal","enrollment":38},{"nctId":"NCT03296800","phase":"PHASE1","title":"Study to Evaluate Effects of Probenecid, Rifampin and Verapamil on Bexagliflozin in Healthy Subjects","status":"COMPLETED","sponsor":"Theracos","startDate":"2017-09-27","conditions":"Type 2 Diabetes Mellitus","enrollment":48},{"nctId":"NCT02178592","phase":"PHASE3","title":"Open-label Study of Dolutegravir (DTG) or Efavirenz (EFV) for Human Immunodeficiency Virus (HIV) - Tuberculosis (TB) Co-infection","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2015-01-23","conditions":"Infection, Human Immunodeficiency Virus, HIV Infections","enrollment":113},{"nctId":"NCT02253420","phase":"PHASE1","title":"COPANLISIB (BAY80-6946) Drug-drug Interaction and Cardiovascular Safety Study in Advanced Solid Tumor and Non-Hodgkin's Lymphoma Patients","status":"COMPLETED","sponsor":"Bayer","startDate":"2014-10-08","conditions":"Medical Oncology","enrollment":51},{"nctId":"NCT04121078","phase":"PHASE1","title":"A Study to Evaluate the Effect of Single-Dose Intravenous Rifampin as a Prototypic Inhibitor of Organic Anion Transporting Polypeptide (OATP) 1B1 and OATP1B3 on the Single-Dose Pharmacokinetics (PK) of Oral TAK-906 in Healthy Adult Participants","status":"COMPLETED","sponsor":"Millennium Pharmaceuticals, Inc.","startDate":"2019-10-15","conditions":"Healthy Volunteers","enrollment":12},{"nctId":"NCT02706535","phase":"PHASE1","title":"A Cross-over Study to Evaluate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics (PK) of GSK525762 in Healthy Female Subjects of Non Child Bearing Potential","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-05-05","conditions":"Drug Interactions, Neoplasms","enrollment":29},{"nctId":"NCT04485156","phase":"PHASE3","title":"Treatment Shortening of Drug-Sensitive Pulmonary Tuberculosis Using High Dose Rifampicin (Hi-DoRi-3)","status":"NOT_YET_RECRUITING","sponsor":"Seoul National University Hospital","startDate":"2020-09","conditions":"Tuberculosis, Pulmonary","enrollment":926},{"nctId":"NCT00476853","phase":"PHASE2","title":"Efficacy Safety Study Comparing 2 Doses of NVP After Initiating Rifampin-containing TB Therapy","status":"COMPLETED","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2005-10","conditions":"HIV Infections, Tuberculosis","enrollment":42},{"nctId":"NCT03353857","phase":"PHASE1","title":"Drug-drug Interaction Between Rifampicin and Progestins/Ethinylestradiol and Midazolam","status":"COMPLETED","sponsor":"Bayer","startDate":"2017-11-29","conditions":"Biological Availability","enrollment":68},{"nctId":"NCT03586726","phase":"PHASE1","title":"A Study to Investigate the Effect of Rifampicin on the PK of Multiple Doses of Balovaptin In Healthy Volunteers","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2018-07-24","conditions":"Healthy Volunteers","enrollment":16},{"nctId":"NCT04150367","phase":"","title":"Efficacy and Safety of Intravenous Treatment of Tuberculosis","status":"TERMINATED","sponsor":"Yuria-Pharm","startDate":"2017-03-03","conditions":"Tuberculosis, Pulmonary","enrollment":166},{"nctId":"NCT03563599","phase":"PHASE2","title":"A Phase 2 Study to Evaluate Early Bactericidal Activity, Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of Telacebec (Q203)","status":"COMPLETED","sponsor":"Qurient Co., Ltd.","startDate":"2018-07-23","conditions":"Treatment-naïve, Sputum Smear-positive Patients With Drug-sensitive Pulmonary TB","enrollment":60},{"nctId":"NCT03758469","phase":"PHASE1","title":"A Study Evaluating Drug-Drug Interaction (DDI) Between HSK3486 Injectable Emulsion and Rifampin Capsules","status":"COMPLETED","sponsor":"Sichuan Haisco Pharmaceutical Group Co., Ltd","startDate":"2018-12-14","conditions":"Anesthesia, Sedation","enrollment":16},{"nctId":"NCT02114684","phase":"PHASE1, PHASE2","title":"Improving Retreatment Success (IMPRESS)","status":"COMPLETED","sponsor":"Centre for the AIDS Programme of Research in South Africa","startDate":"2013-11","conditions":"Recurrent Tuberculosis","enrollment":197},{"nctId":"NCT02193776","phase":"PHASE2","title":"A Phase 2 to Evaluate the Efficacy, Safety and Tolerability of Combinations of Bedaquiline, Moxifloxacin, PA-824 and Pyrazinamide in Adult Subjects With Drug-Sensitive or Multi Drug-Resistant Pulmonary Tuberculosis.","status":"COMPLETED","sponsor":"Global Alliance for TB Drug Development","startDate":"2014-10-23","conditions":"Tuberculosis","enrollment":240},{"nctId":"NCT02412436","phase":"PHASE2","title":"PK Study of Rifampicin Interactions With DMPA and Efavirenz in TB","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2015-11-03","conditions":"HIV-1 Infection, Tuberculosis","enrollment":62},{"nctId":"NCT03755778","phase":"PHASE1","title":"Drug-Drug Interaction Study Between EDP-938, Itraconazole, Rifampin, and Quinidine in Healthy Subjects","status":"COMPLETED","sponsor":"Enanta Pharmaceuticals, Inc","startDate":"2018-11-29","conditions":"RSV Infection","enrollment":72},{"nctId":"NCT03624959","phase":"PHASE1","title":"Drug-drug Interaction Study of Ozanimod With Inhibitor or Inducer of CYP2C8 and/or CYP3A","status":"COMPLETED","sponsor":"Celgene","startDate":"2018-06-20","conditions":"Healthy Volunteer","enrollment":100},{"nctId":"NCT02342886","phase":"PHASE3","title":"Shortening Treatment by Advancing Novel Drugs","status":"COMPLETED","sponsor":"Global Alliance for TB Drug Development","startDate":"2015-02","conditions":"Tuberculosis, Pulmonary, Drug Sensitive, Tuberculosis, Pulmonary, Multi Drug-resistant","enrollment":284},{"nctId":"NCT03281226","phase":"PHASE2","title":"RIPE vs RIPE Plus N-acetylcysteine in Patients With HIV/TB Co-infection","status":"UNKNOWN","sponsor":"Fundação de Medicina Tropical Dr. Heitor Vieira Dourado","startDate":"2016-12-07","conditions":"Tuberculosis, Pulmonary, HIV/AIDS","enrollment":50},{"nctId":"NCT02273765","phase":"PHASE3","title":"Raltegravir Versus Efavirenz in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuberculosis","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2015-09-11","conditions":"HIV-1 Infection, Tuberculosis","enrollment":460},{"nctId":"NCT01516203","phase":"PHASE2","title":"Phase 2a EBA Trial of AZD5847","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2012-12-05","conditions":"Tuberculosis","enrollment":75},{"nctId":"NCT03048110","phase":"PHASE1","title":"Drug-drug Interaction (DDI) Study to Assess ODM-201 as a Victim of CYP3A4 Inhibition or Induction","status":"COMPLETED","sponsor":"Bayer","startDate":"2017-02-15","conditions":"Biological Availability","enrollment":15},{"nctId":"NCT03346837","phase":"PHASE1","title":"A Study to Evaluate the Effect of 2 Drugs on the Pharmacokinetics of BMS-986205 in Healthy Subjects","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2017-11-22","conditions":"Malignancies Multiple","enrollment":53},{"nctId":"NCT00814671","phase":"PHASE2","title":"Study of Daily Rifapentine for Pulmonary Tuberculosis","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2010-04","conditions":"Tuberculosis","enrollment":153},{"nctId":"NCT03213145","phase":"PHASE1","title":"Drug-drug Interaction Study Between EDP-305, Intraconazole and Rifampin in Healthy Volunteers","status":"COMPLETED","sponsor":"Enanta Pharmaceuticals, Inc","startDate":"2017-07-11","conditions":"NASH - Nonalcoholic Steatohepatitis","enrollment":48},{"nctId":"NCT02975570","phase":"PHASE3","title":"Efficacy and Tolerability of Delamanid, Linezolid, Pyrazinamide and Levofloxacin","status":"WITHDRAWN","sponsor":"Boston University","startDate":"2017-08","conditions":"Tuberculosis Multi Drug Resistant Active","enrollment":""},{"nctId":"NCT00728507","phase":"PHASE2","title":"Rifapentine Plus Moxifloxacin for Treatment of Pulmonary Tuberculosis","status":"TERMINATED","sponsor":"Johns Hopkins University","startDate":"2009-11","conditions":"Tuberculosis","enrollment":121},{"nctId":"NCT01399788","phase":"PHASE1","title":"A Bioequivalence Study Comparing A Fixed Dose Combination Formulation Of Myrin P Forte That Contains Rifampicin, Isoniazid, Ethambutol And Pyrazinamide Per Tablet To An Equivalent Dose Of Single Drug Reference Preparations Of Similar Combination Following Oral Administration In Healthy Adults","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-07","conditions":"Healthy Volunteers","enrollment":36},{"nctId":"NCT01591850","phase":"PHASE1","title":"A Drug-Drug Interaction Study of Ketoconazole, Rifampicin and Ritonavir-Boosted Atazanavir With Single-Dose RO5093151 in Healthy Volunteers","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-09","conditions":"Healthy Volunteer","enrollment":51},{"nctId":"NCT01225640","phase":"PHASE2","title":"PNU-100480 In Newly Diagnosed, Drug Sensitive Patients With Pulmonary TB; Early Bactericidal Activity; Whole Blood Assay","status":"COMPLETED","sponsor":"Sequella, Inc.","startDate":"2011-08","conditions":"Tuberculosis","enrollment":59},{"nctId":"NCT01386593","phase":"PHASE1","title":"Pharmacokinetic Study to Characterize Phenotyping Metrics of the \"Basel\" Cocktail After CYP Induction or Inhibition","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2011-05","conditions":"Metabolic Detoxication, Phase I","enrollment":16},{"nctId":"NCT01994460","phase":"PHASE2","title":"Linezolid Instead of Ethambutol in Treatment of Drug-susceptible Tuberculosis","status":"UNKNOWN","sponsor":"Seoul National University Hospital","startDate":"2014-01","conditions":"Pulmonary Tuberculosis Without Resistance to Rifampicin","enrollment":429},{"nctId":"NCT01322438","phase":"PHASE1","title":"Effect of Rifampin on the Pharmacokinetics of BAY73-4506","status":"COMPLETED","sponsor":"Bayer","startDate":"2011-03","conditions":"Neoplasms","enrollment":24},{"nctId":"NCT02138799","phase":"PHASE1","title":"A Study to Evaluate How a Drug That Alters Liver Enzymes (Rifampin) Affects the Metabolism of Enzalutamide in Men","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2013-07","conditions":"Drug-Drug Interaction (DDI), Healthy Subjects, Pharmacokinetics of Enzalutamide","enrollment":28},{"nctId":"NCT02014272","phase":"PHASE1","title":"A Bioequivalence Study Comparing A Fixed Dose Combination Formulation, Rin 150 And Individual Reference Drugs In Healthy Volunteers","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-09","conditions":"Healthy Volunteers","enrollment":28},{"nctId":"NCT01757236","phase":"PHASE2","title":"Efficacy and Safety Study of Antibiotic Treatment to Treat Hip Prosthetic Joint Infection","status":"UNKNOWN","sponsor":"University Hospital, Tours","startDate":"2012-10","conditions":"Hip Prosthetic Joint Infection","enrollment":100},{"nctId":"NCT02123628","phase":"PHASE4","title":"Antibiotic Treatment Duration for Non-Surgically-Treated Diabetic Foot Osteomyelitis","status":"COMPLETED","sponsor":"Tourcoing Hospital","startDate":"2007-06","conditions":"Diabetes Mellitus","enrollment":40},{"nctId":"NCT00822315","phase":"PHASE2","title":"Efficacy and Safety of 2 Raltegravir Doses in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuberculosis","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2009-07","conditions":"HIV Infections, Tuberculosis","enrollment":155},{"nctId":"NCT00741169","phase":"PHASE1","title":"TMC435350-TiDP16-C105: Phase I, 3-way Crossover, Drug-drug Interaction Between TMC435350 and Rifampin After Multiple Dosing.","status":"COMPLETED","sponsor":"Tibotec Pharmaceuticals, Ireland","startDate":"2008-06","conditions":"Hepatitis C, HCV, Tuberculosis","enrollment":21},{"nctId":"NCT01311505","phase":"PHASE1","title":"Bioequivalence Study Comparing Rifampicin In A Fixed-Dose Combination (Rifampicin+Isoniazid, Myrin© 2) And The Reference Drug (Rifampicin, Rimactane®)","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-04","conditions":"Tuberculosis","enrollment":21},{"nctId":"NCT01426906","phase":"PHASE1","title":"Pharmacokinetic Drug Interaction Study in Healthy Male Subjects","status":"COMPLETED","sponsor":"LG Life Sciences","startDate":"2011-01","conditions":"Healthy Male Volunteers","enrollment":24},{"nctId":"NCT01336218","phase":"PHASE1","title":"Effects of Administration of Fostamatinib on Blood Concentrations of Rifampicin in Healthy Subjects.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2011-04","conditions":"Rheumatoid Arthritis, Healthy Volunteers","enrollment":15},{"nctId":"NCT00948077","phase":"NA","title":"Pharmacokinetic Study for Anti-tuberculosis Drugs","status":"UNKNOWN","sponsor":"Taipei Medical University WanFang Hospital","startDate":"2009-07","conditions":"Pulmonary Tuberculosis","enrollment":16},{"nctId":"NCT00767975","phase":"PHASE3","title":"Active Screening of Latent TB Infection, Treatment and Long Term Follow-up in Prison","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2008-01","conditions":"Tuberculosis","enrollment":2384}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":34,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"rifampin, randomized, open label","genericName":"rifampin, randomized, open label","companyName":"National Taiwan University Hospital","companyId":"national-taiwan-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rifampin is a small molecule inhibitor of bacterial DNA-directed RNA polymerase, classified as an INHIBITOR. It is used to treat conditions such as tuberculosis, pulmonary tuberculosis, and HIV-1 infection, among others, as indicated by ClinicalTrials.gov.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}